CD81 alone is not a reliable marker to quantitate CLL cells but it is often included in a combination of markers (including for examples CD43, CD200, ROR1 and CD81) to quantify the residual disease and to optimize the identification of the CLL pathology [111]. The gene discussed is CD200; the disease is B-cell chronic lymphocytic leukemia.